ROS1 act mut
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ROS1
Variant act mut
Impact List unknown
Protein Effect gain of function
Gene Variant Descriptions ROS1 act mut indicates that this variant results in a gain of function in the Ros1 protein. However, the specific amino acid change has not been identified.
Associated Drug Resistance
Category Variants Paths

ROS1 mutant ROS1 act mut

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04169841 Phase II Durvalumab + Olaparib + Tremelimumab Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) Active, not recruiting FRA 0
NCT05785754 Phase I Doxorubicin + Tebentafusp DCSZ11 + Pembrolizumab DCSZ11 DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors Recruiting USA | AUS 2
NCT03868423 Phase II Brigatinib Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Withdrawn USA 0
NCT02473497 Expanded access Crizotinib Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients No longer available USA 0
NCT03679767 Phase II Retifanlimab A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Completed USA | ROU | POL | ITA | HUN | FRA | ESP | AUT 0
NCT04166487 Phase II Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium Plasma-Adapted First-Line Pembro in NSCLC Active, not recruiting USA 0
NCT03665129 Phase I Avdoralimab + Durvalumab IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) Terminated USA | FRA 0
NCT03993873 Phase Ib/II Elzovantinib Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) Active, not recruiting USA | FRA | ESP 2
NCT05825625 Phase II Atezolizumab + Tiragolumab NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing Active, not recruiting DEU 0
NCT05435846 Phase I Capmatinib + Trametinib Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation Terminated USA 0
NCT04683250 Phase Ib/II Vepafestinib Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities (MARGARET) Recruiting USA 1
NCT05176665 Phase Ib/II EMB-01 EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers Recruiting USA 1
NCT03175224 Phase Ib/II Vebreltinib APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) Recruiting USA | ITA | HUN | GBR | FRA | ESP | CAN | AUS 3
NCT03953235 Phase Ib/II GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens Completed USA 0
NCT04222972 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pralsetinib Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Completed TUR | SWE | POL | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CHE | BRA | BEL | AUS | ARG 6
NCT05513703 Phase II Telisotuzumab vedotin A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Terminated USA | ITA | ISR | FRA | DEU | AUS 3
NCT04116541 Phase II Alectinib Dabrafenib + Trametinib Cabozantinib Avapritinib A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) Recruiting FRA 0
NCT03181308 Phase I Carotuximab + Nivolumab Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC Completed USA 0